This is the text extract for Notification for efavirenz (Stocrin); Contact: Greg Williams, browse documents here.

3 November 2011

Approval of proposal to amend the terms of listing for efavirenz (Stocrin)

PHARMAC is pleased to announce the approval of an agreement with Merck Sharp and Dohme (New Zealand) Limited (MSD) for efavirenz (Stocrin). This was the subject of a consultation letter dated 22 September 2011. In summary, the effect of the decision is that:  From 1 January 2012, Stocrin will remain listed in Section B of the Pharmaceutical Schedule at the following prices and subsidies (ex-manufacturer, excluding GST):

Chemical Efavirenz Efavirenz Efavirenz Presentation 50 mg tablet 200 mg tablet 600 mg tablet Brand Stocrin

S29

Pack size 30 90 30

Price and subsidy $158.33 $474.99 $474.99

Stocrin Stocrin



Stocrin will remain funded in the community subject to the Special Authority currently applying to all antiretrovirals; From 1 January 2012 a rebate will apply to all community dispensings of Stocrin reducing the net price to the funder; and Stocrin will have subsidy and delisting protection until subsidy and delisting protection until 30 June 2015.

 

Feedback received All consultation responses received by 6 October 2011 were considered in their entirety in making a decision on the proposed changes. One response was received and it was supportive of the proposal. More information If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

A462021 Page 1 of 1